



DermTech Announces Expansion of Board of Directors and Commercial Team

LA JOLLA (July 11, 2016) – DermTech, Inc., an emerging diagnostics company focusing on non-invasive gene expression tests for skin cancer and inflammatory diseases, announced today it has added Mr. Matthew Posard to its Board of Directors. Additionally, DermTech announced the continued expansion of its commercial team with regional sales personnel.

“Matt has over 25 years of general management and commercial experience in the life sciences, molecular diagnostics and consumer genomics industry and has a distinguished reputation in commercializing transformative novel products and technology in the genomics space. We are excited to welcome him to the Board of Directors to contribute his commercial experience to DermTech at this exciting time of commercial growth,” said Dr. John Dobak, DermTech CEO.

Mr. Posard held influential leadership roles with market leading companies including Illumina, Trovagene, Biosite/Alere and Gen-Probe. Mr. Posard was key in leading Illumina to its first \$1B in revenue and was Senior Vice President responsible for its entry into the clinical, forensics and consumer genomics markets. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego and currently serves as a board member for Halozyne Therapeutics, SlipChip Corporation, Omicia and Envision Genomics.

About DermTech

DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and inflammatory skin conditions. DermTech operates a CLIA licensed and CAP accredited laboratory in the company’s La Jolla, CA headquarters. DermTech’s technology allows the analysis of skin biopsy samples collected *non-invasively* using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.

Contacts

DermTech, Inc.
Sarah Dennison, MBA
VP of Marketing
(858) 450-4222
sdennison@dermtech.com